The U.S. market for epinephrine is developing because of increased prevalence of allergies, emergency preparedness initiatives, institutional stocking, competitive generic drugs, and innovative delivery systems that increase accessibility of treatment. As the treatment of choice in the management of anaphylaxis, epinephrine is commonly prescribed in the domestic environment, schools, healthcare settings, EMS, and public places. Meanwhile, auto-injector devices are currently popular, but needleless nasal spray devices offer some new prospects due to simplified administration and safety issues connected with injectable drugs.
SNS Insider says the value of the U.S. Epinephrine Market in 2025 is estimated to be USD 1.06 billion, with further growth forecasted to USD 2.13 billion by 2035, which indicates a CAGR of 9.13% between 2026 and 2035. At the same time, the Global Epinephrine Market size is expected to be worth USD 2.77 billion in 2025 and grow up to USD 6.91 billion by 2035 with a CAGR of 9.57%.
Gain Actionable Intelligence on the Epinephrine Market – Request a Free Sample Report
Why the U.S. Is a Key Epinephrine Market
The United States is the largest consumer of epinephrine within North America owing to a high occurrence of allergies, good healthcare infrastructure, favorable reimbursement scenario, and emergency preparedness measures.
According to the report, about 25.7% of adult Americans suffer from seasonal allergies, and 6.2% suffer from food allergies treatment, leading to strong demand for emergency epinephrine products. Moreover, stocking of epinephrine at schools in many states increases demand for such products due to increased institutional purchases.
Approximately 42.4% share of global revenue was generated in North America in 2025, where the United States is the key country.
Auto-Injectors Continue to Lead Product Demand
The auto-injector segment continued to dominate the market in 2025 owing to easy application, patient familiarity, suitability in emergencies, and availability at schools, homes, workplaces, and other public places.
EpiPen and AUVI-Q are some examples of products that have made auto-injectors an acknowledged emergency treatment form. Availability of generic products has further helped reduce some of the affordability barriers for patients. On the contrary, nasal sprays are likely to show the highest growth rate until 2035 owing to the commercial availability of a needle-less delivery form.
Nasal Epinephrine Is Changing Emergency Treatment
Nasal delivery of epinephrine is considered one of the most significant innovations that have impacted the U.S. market. The use of sprays may help avoid the pain associated with injections and may remove the need to inject a drug using a needle in case of an emergency.
The fact that Neffy was created by the company ARS Pharmaceuticals is an illustration of increasing commercial value of nasal epinephrine. These drugs could be especially useful in the case of children.
Anaphylaxis Remains the Largest Application
Anaphylaxis made up for about 68.61% of the epinephrine market share in 2025, driven by the rising incidence of food allergy, drug allergy, and insect venom sensitivity.
The existing position of epinephrine as first-line drug treatment for severe allergies is further driving this market segment. There would be further growth in the area of cardiac arrest owing to the rising use of prefilled epinephrine syringes in the area. The retail and online pharmacies held about 77.64% share of the distribution market in 2025, while there would be rapid growth in hospital pharmacies during the forecast period.
Companies Shaping the U.S. Epinephrine Market
Glenmark Pharmaceuticals
In February 2025, Glenmark Pharmaceuticals extended its epinephrine reach in the United States by launching a generic epinephrine injection multiple dose vial. This drug had exclusivity for 180 days and thus increased the level of competition in the United States injectable epinephrine market. The launch is one of the ways through which generic manufacturers seek to increase access to cheaper emergency drugs. Generic epinephrine would enable hospitals, health practitioners, and patients to have an alternative to expensive brand-name drugs.
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals improved its position in the epinephrine market by acquiring the epinephrine injection product line of Bausch Health in 2025. This move added to the company’s range of products containing injectable epinephrine and helped enhance its capacity to manufacture epinephrine injection solutions. This is because there remains an increasing need for epinephrine not just in consumer auto-injector form, but also for usage in emergency rooms, critical care areas, and other clinical facilities.
Kaleo Inc.
Kaleo launched a new-generation AUVI-Q auto-injector with voice-guided step-by-step instructions for administering medication. The idea behind this design was to make the product user-friendly for patients and carers who might have little or no knowledge about the procedure in case of an allergic reaction and need to follow some directions. Usability-centered innovation is still relevant for the U.S. epinephrine market since this kind of treatment usually takes place outside the clinical setting. Ease of use could contribute to emergency preparation and make auto-injectors a valuable product line despite the rise of nasal delivery systems.
Digital Technology Is Emerging in Allergy Management
Future epinephrine delivery mechanisms may feature Bluetooth-enabled technology, expiration alerts, app-based reminders, device tracking features, and emergency location services. These components may allow for integration of epinephrine delivery devices into an overall allergy treatment system instead of being a standalone emergency system.
Telepharmacy and digital healthcare applications can increase compliance through patient alerts about replacing the devices and accessing prescriptions.
U.S. Epinephrine Outlook Through 2035
The growth of the U.S. Epinephrine Market is predicted to continue through 2035 due to rising allergy prevalence, stocking demands, generics, nasal spray use, and advances in delivery systems. With the U.S. Epinephrine Market forecasted to reach USD 2.13 billion in 2035, it is expected that competition in the market will shift towards cost effectiveness, convenience of administration, accessibility, and delivery systems.
